Supernus Pharma (NASDAQ: SUPN) reported Q2 GAAP EPS of ($0.02), which may not compare to the analyst estimate of $0.22. Revenue for the quarter came in at $135.56 million versus the consensus estimate of $144.53 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.